Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

This is a first-in-human, first-in-class, escalating dose trial of an antibody that inhibits
an anti-apoptotic signal in human macrophages. The major aims of the study are to define the
safety profile of this new drug, and to determine a recommended dose and schedule for
potential additional trials.

Inclusion Criteria:

Patients with histologically or cytologically confirmed advanced solid malignancy or
Lymphoma

Relapsed or refractory disease after at least 1 prior systemic treatment for the primary
malignancy and not a candidate for other curative treatment.

Adequate hematologic status

Adequate coagulation function

Adequate hepatic function

Adequate renal function

Exclusion Criteria:

Known primary tumors of central nervous system disease

Known active brain metastases

Known cardiopulmonary disease